{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:36:59Z","timestamp":1762609019312,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13318-022-00804-6","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T20:05:14Z","timestamp":1668801914000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"48","author":[{"given":"Ran","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Prokopienko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"1","key":"804_CR1","first-page":"97","volume":"151","author":"M Briskin","year":"1997","unstructured":"Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, et\u00a0al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1):97\u2013110.","journal-title":"Am J Pathol"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0065-2776(08)60022-X","volume":"72","author":"EC Butcher","year":"1999","unstructured":"Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol. 1999;72:209\u201353.","journal-title":"Adv Immunol"},{"issue":"2","key":"804_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","volume":"153","author":"DJ Erle","year":"1994","unstructured":"Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994;153(2):517\u201328.","journal-title":"J Immunol"},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.0105-2896.2005.00285.x","volume":"206","author":"M Salmi","year":"2005","unstructured":"Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev. 2005;206:100\u201313.","journal-title":"Immunol Rev"},{"issue":"3","key":"804_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"804_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40261-016-0437-4","volume":"36","author":"M Rosario","year":"2016","unstructured":"Rosario M, Wyant T, Leach T, Sankoh S, Scholz C, Parikh A, et\u00a0al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. Clin Drug Investig. 2016;36(11):913\u201323.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"804_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.13243","volume":"42","author":"M Rosario","year":"2015","unstructured":"Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et\u00a0al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42(2):188\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Supplement","key":"804_CR8","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.14309\/01.ajg.0000592236.99685.5c","volume":"114","author":"L Yang","year":"2019","unstructured":"Yang L, Dobler I, Agboton C, Osborn T, Smithson G. Measuring serum vedolizumab and antibodies to vedolizumab: comparison of four commercially available clinical laboratory assays to the assay used in vedolizumab development: 675. Am J Gastroenterol. 2019;114(Supplement):S396\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"804_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1208\/s12248-020-00518-0","volume":"23","author":"T Wyant","year":"2020","unstructured":"Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL assay for vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 GEMINI trials. AAPS J. 2020;23(1):3.","journal-title":"AAPS J"},{"issue":"1\u20132","key":"804_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","volume":"264","author":"C Milch","year":"2013","unstructured":"Milch C, Wyant T, Xu J, Parikh A, Kent W, Fox I, et\u00a0al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264(1\u20132):123\u20136.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"804_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, et\u00a0al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"9","key":"804_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","volume":"53","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, et\u00a0al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048\u201364.","journal-title":"J Gastroenterol"},{"issue":"2","key":"804_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jcph.1307","volume":"59","author":"K Kobayashi","year":"2019","unstructured":"Kobayashi K, Suzuki Y, Watanabe K, Oda K, Mukae M, Yamada A, et\u00a0al. A phase 1, multiple-dose study of vedolizumab in Japanese patients with ulcerative colitis. J Clin Pharmacol. 2019;59(2):271\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"804_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","volume":"56","author":"M Rosario","year":"2017","unstructured":"Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, et\u00a0al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56(11):1287\u2013301.","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T09:21:29Z","timestamp":1672996889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00804-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"25 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Takeda Development Center Asia, Pte. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lili Yang, Alexander Prokopienko, and Hiroyuki Okamoto are employees of Takeda, which sponsored the clinical trial. Lili Yang, Alexander Prokopienko, and Hiroyuki Okamoto also own stock and\/or stock options in Takeda. Other authors have no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki and Good Clinical Practice Guidelines. The study was approved by the Ethics Committee of Peking University First Hospital (China).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects provided written informed consent prior to participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Considered upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Y.C. and X.Z. contributed to the design of the study. Y.C., X.Z., R.X., N.Z., and B.J. performed the research and interpreted the data. Preparation of the initial manuscript was carried out by R.X. and N.Z. The manuscript was revised and approved by R.X., N.Z., B.J., X.Z., and Y.C. L.Y. contributed to exporting serum samples from China by providing technical\/scientific rationale to OHGRA, overseeing the smooth running of the technical operations during the study in China, answering Chinese regulatory immunogenicity and neutralizing questions, providing the assay information, and reviewing this manuscript. A.P. contributed to the interpretation of the data and writing and reviewing the manuscript. H.O. contributed to the design of the study, analysis, and interpretation of the data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}